RARE Ultragenyx Pharmaceutical Inc.

76.91
+0.09  (0.12%)
Previous Close 76.82
Open 78.25
Price To book 6.75
Market Cap 3.14B
Shares 40,859,000
Volume 708,333
Short Ratio 15.47
Av. Daily Volume 463,106

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released July 2016. Primary endpoint hit. Secondary missed. BLA filing due 1H 2017.
rhGUS
Mucopolysaccharidosis 7 (MPS 7)
Phase 3 to be initiated 1H 2017.
UX007 (triheptanoin)
Glut1 DS patients with the movement disorder phenotype
Phase 3 data due 2H 2017.
Aceneuramic acid extended release (Ace-ER)
GNE Myopathy
Phase 3 enrolment completed July 2016. Data due 1H 2017.
KRN23
X-Linked Hypophosphatemia (XLH) - adult
Interim data released April 2016. Additional data released September 2016.
KRN23
Tumor-induced osteomalacia (TIO)
Phase 3 enrollment commenced October 2016.
KRN23
X-Linked Hypophosphatemia (XLH) - pediatric
Phase 2 initiated March 2014. Seizure data due 1Q 2017.
UX007 (triheptanoin)
Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Phase 2 interim data released October 2015. 78-week data released November 30, 2016. Phase 3 planned for 2017.
UX007 (triheptanoin)
Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

Latest News

  1. Baron Opportunity Fund Comments on Ultragenyx Pharmaceutical
  2. ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 10-K, Annual Report
  3. Edited Transcript of RARE earnings conference call or presentation 16-Feb-17 10:00pm GMT
  4. Ultragenyx reports 4Q loss
  5. Ultragenyx reports 4Q loss
  6. ULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
  7. Ultragenyx Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Update
  8. Q4 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close
  9. Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More
  10. Ultragenyx to Present at Leerink Partners Global Healthcare Conference
  11. Ultragenyx to Host Conference Call for Fourth Quarter and Full Year 2016 Financial Results and Corporate Update
  12. Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : February 1, 2017
  13. Ultragenyx's (RARE) KRN23 Accepted for Review in the EU
  14. Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : January 5, 2017
  15. Ultragenyx and Kyowa Kirin International Announce Marketing Authorization Application for KRN23 Filed and Accepted for Review by European Medicines Agency
  16. Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines Agency(106KB)
  17. Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines Agency
  18. Ultragenyx and Kyowa Kirin International Announce Marketing Authorization Application for KRN23 Filed and Accepted for Review by European Medicines Agency
  19. Ultragenyx to Present at J.P. Morgan Healthcare Conference
  20. Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : December 23, 2016